Clinical Trials

14 enrolled

Waldenstrom Macroglobulinemia, Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT06456463 2026-03-09

TRILLIUM

83 enrolled

Leukemia, Myeloid, Acute

NCT06524375 2026-02-25

BRAVE

118 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04895436 2026-02-09

ReVenG

75 enrolled

Phase 2 Not yet recruiting

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07024706 2026-01-21

MAVRiC

80 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04150029 2026-01-13

STIMULUS-AML1

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

MyeloidOther hematologic neoplasm

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

110 enrolled

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07154264 2025-12-24

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT05951959 2025-10-21

TrAVeRse

108 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06384261 2025-09-10

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

120 enrolled

Leukemia, Myeloid, Acute

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

156 enrolled

Multiple Myeloma, Neoplasms

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

120 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04477486 2025-07-09

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

13 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT06191263 2025-04-13

RIVER-81

98 enrolled

Leukemia, Myeloid, Acute

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

54 enrolled 26 charts

Myeloid Malignancies

NCT04905407 2025-02-24

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

66 enrolled 21 charts

Leukemia, Myeloid, Acute

NCT06115135 2025-01-16

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

39 enrolled

Multiple Myeloma

NCT02910583 2024-12-20

Captivate

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

41 enrolled 4 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05209308 2023-03-16

CORAL

Phase 2 Withdrawn

Leukemia

NCT02141282 2022-12-19

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

127 enrolled 17 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

14 enrolled 19 charts

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT03584009 2022-06-28

Veronica

103 enrolled 19 charts

Breast

Breast Neoplasms

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01889186 2021-12-16

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

158 enrolled 21 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

8 enrolled 12 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT03785184 2019-08-28

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Phase 2 Withdrawn

Multiple Myeloma, Neoplasms

NCT02187861 2019-06-05

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

163 enrolled 30 charts

Lymphoma, Follicular

NCT01994837 2018-06-06

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

32 enrolled 14 charts